SuperworthRein Therapeutics shares outstanding RNTX
Diluted shares outstanding, averaged over each quarter, from 2016.
- Latest quarter, to Jun 30, 2026
- 67.1M
- On a year earlier
- +177.4%
- more shares
Rein Therapeutics had 67.1M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 177.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 29.2M | +35% |
| FY2024 | 21.7M | +354% |
| FY2023 | 4.8M | +5% |
| FY2022 | 4.5M | +0% |
| FY2021 | 4.5M | +121% |
| FY2020 | 2M | +47% |
| FY2019 | 1.4M | +89% |
| FY2018 | 737.3K | +0% |
| FY2017 | 736K | +3304% |
| FY2016 | 21.6K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 67.1M | +177% | |
| Q1 FY26 | 30.4M | +39% | |
| Q4 FY25 | 29.2M | +35% | |
| Q3 FY25 | 26.4M | +22% | |
| Q2 FY25 | 24.2M | +21% | |
| Q1 FY25 | 21.9M | +164% | |
| Q4 FY24 | 21.7M | +354% | |
| Q3 FY24 | 21.7M | +377% | |
| Q2 FY24 | 19.9M | +338% | |
| Q1 FY24 | 8.3M | +83% | |
| Q4 FY23 | 4.8M | +5% | |
| Q3 FY23 | 4.5M | −0% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Rein Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.